PharmaJet® Inc., the developer of a needle-free injection technology to administer medications and vaccines to patients, and bioCSL Inc., the maker of AFLURIA® (Influenza Vaccine) today announced the U.S. Food and Drug Administration (FDA) has approved the PharmaJet Stratis® 0.5mL Needle-Free Jet Injector for delivery of AFLURIA in individuals aged 18 to 64 years. This is the first needle-free delivery system approved by the FDA for the administration of an inactivated influenza vaccine.
“Healthcare providers now have the option of delivering AFLURIA without a needle,” said Ron Lowy, PharmaJet CEO and co-chairman. “The PharmaJet injection technology is an especially important innovation for the millions of individuals who suffer from fear of needles and who consequently forego their annual flu vaccination. We believe this is a significant step forward in the effort to improve public health through broader immunization coverage, as well as improved safety of caregivers.”
Common Management Taxonomy: